Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003876038 | SCV004677433 | uncertain significance | Long QT syndrome | 2024-01-15 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with serine, which is neutral and polar, at codon 33 of the KCNE1 protein (p.Arg33Ser). This variant is present in population databases (rs771964597, gnomAD 0.002%). This variant has not been reported in the literature in individuals affected with KCNE1-related conditions. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on KCNE1 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004369589 | SCV005033002 | uncertain significance | Cardiovascular phenotype | 2023-10-03 | criteria provided, single submitter | clinical testing | The p.R33S variant (also known as c.99G>T), located in coding exon 1 of the KCNE1 gene, results from a G to T substitution at nucleotide position 99. The arginine at codon 33 is replaced by serine, an amino acid with dissimilar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Roden Lab, |
RCV004780682 | SCV005393041 | not provided | Long QT syndrome 5 | no assertion provided | in vitro |